Albert M. Kim

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

Paul M. Ridker, Jean‐Claude Tardif, Pierre Amarenco et al. · New England Journal of Medicine · 2017 · 364 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez et al. · Nature Medicine · 2021 · 219 citations

Medicine, Pharmacology, Pharmacotherapy +9

Intracardiac and extracardiac markers of inflammation during atrial fibrillation

Gregory M. Marcus, Lisa M. Smith, Karen Ordovás et al. · Heart Rhythm · 2009 · 160 citations

Medicine, Cardiology, Internal Medicine +14

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Aditi R. Saxena, Donal Gorman, Ryan M. Esquejo et al. · Nature Medicine · 2021 · 142 citations

Medicine, Endocrinology, Pharmacology +10

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Albert M. Kim, Veena Somayaji, Jennifer Dong et al. · Diabetes Obesity and Metabolism · 2017 · 139 citations

Pharmacy, Pharmacokinetics, Pharmacology +17